MPM Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

MPM Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,809,677	Closed	-$1.15M	–	5
2025 Q2	$1.15M	Sell	4,809,677 -526,038	-10%	-$140K	2.66%	5
2025 Q1	$1.05M	Sell	5,335,715 -219,746	-4%	-$114K	1.51%	6
2024 Q4	$2.99M	Hold	5,555,461	–	–	2.41%	5
2024 Q3	$5.28M	Hold	5,555,461	–	–	3.63%	6
2024 Q2	$5.42M	Hold	5,555,461	–	–	2.97%	6
2024 Q1	$8.78M	Hold	5,555,461	–	–	3.58%	6
2023 Q4	$4.41M	Sell	5,555,461 -731,640	-12%	-$412K	2.16%	6
2023 Q3	$4.9M	Hold	6,287,101	–	–	2.63%	6
2023 Q2	$5.82M	Buy	+6,287,101	New	+$7.5M	2.85%	6

Other funds holding ADAP

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

MPM Asset Management's ADAP Position: Q3 2025 in Review

MPM Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 4,809,677 shares — an estimated $1.15M sold.

MPM Asset Management first reported a position in ADAP in Q2 2023 and held it in 9 quarters. The position peaked at $8.78M in Q1 2024. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

MPM Asset Management reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
MPM Asset Management sold 4,809,677 Adaptimmune Therapeutics shares in Q3 2025, an estimated $1.15M.
MPM Asset Management first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 9 quarters.
MPM Asset Management's Adaptimmune Therapeutics position peaked at $8.78M in Q1 2024.
55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on MPM Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.